What emerging disruptive technologies challenge our portfolio, and how do we future-proof our strategy?

Driven by emerging approaches in precision medicine and diagnostics, and novel technologies that enable them, our client sought to identify disruption and align on future scenarios to pressure test their portfolio strategy and ensure a robust approach to innovation.

Eradigm’s thorough assessment of emerging approaches and technologies in diagnostics enabled our client to identify portfolio threats and unique opportunities, pressure tested through an engaging 3-day cross-functional workshop bringing together the senior leadership team, with outputs complementing ongoing strategic decisions.